AI assistant
BOTANIX PHARMACEUTICALS LTD — AGM Information 2023
Aug 30, 2023
64551_rns_2023-08-30_0d5c0391-9889-4421-a023-450bbd62f986.pdf
AGM Information
Open in viewerOpens in your device viewer
==> picture [113 x 51] intentionally omitted <==
31 August 2023
2023 ANNUAL GENERAL MEETING – KEY DATES
In accordance with ASX Listing Rule 3.13.1, Botanix Pharmaceuticals Ltd (ASX:BOT) (“ Botanix ” or the “ Company ”) is pleased to announce the 2023 Annual General Meeting has been scheduled for 9.00am (WST) on Wednesday, 8 November 2023 at the offices of BDO, Level 9, Mia Yellagonga Tower 2, 5 Spring Street, Perth, Western Australia.
An item of business at the AGM will be the re-election of directors. The closing date for the receipt of director nominations is Wednesday, 20 September 2023. Nominations must be received at the Company’s registered office no later than 5.00pm (WST) on Wednesday, 20 September 2023.
Further information on the Annual General Meeting will be provided in the Notice of Annual General Meeting which will be released to ASX on or before Friday, 6 October 2023.
Release authorised by Board of Directors.
About Botanix Pharmaceuticals
Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which is progressing its lead product Sofpironium Bromide for the treatment of primary axillary hyperhidrosis, through FDA approval. A mid-cycle review for the product has been successfully completed by FDA in 1Q 2023, which subject to other information that may be required by FDA, remains on track for approval targeted for the end of September 2023. Sofpironium Bromide is positioned to be a leading first line and second line therapy and potentially represents a safe and effective new option for patients.
The Company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea (successful Phase 1b/2 study in 4Q 2022), dermatitis and acne respectively. Botanix is also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. To learn more please visit: http://www.botanixpharma.com/
For more information, please contact:
General enquiries Investor enquiries Media enquiries Corporate Communications Hannah Howlett Haley Chartres Botanix Pharmaceuticals WE Communications H^CK P: +61 8 6555 2945 P: +61 450 648 064 P: +61 423 139 163 [email protected] [email protected] [email protected]